Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Neck Rhabdoid Tumors: Clinical Features and Consideration of Autologous Stem Cell Transplant

Wolfe, Adam, D., MD, PhD*; Capitini, Christian, M., MD; Salamat, Shahriar, M., MD, PhD; DeSantes, Kenneth, MD; Bradley, Kristin, A., MD§; Kennedy, Tabassum, MD; Dehner, Louis, P., MD; Patel, Neha, J., MD

Journal of Pediatric Hematology/Oncology: January 2018 - Volume 40 - Issue 1 - p e50–e54
doi: 10.1097/MPH.0000000000000829
Online Articles: Clinical and Laboratory Observations
Buy

Extrarenal malignant rhabdoid tumors (MRT) have a poor prognosis despite aggressive therapy. Adding high-dose chemotherapy with autologous stem cell rescue (HDC-ASCR) as consolidative therapy for MRT is controversial. We describe 2 patients, age 13 years and 19 months, with unresectable neck MRT. After chemotherapy and radiotherapy, both underwent HDC-ASCR and remain in remission over 4 years later. We reviewed all published cases of neck MRT, and found poorer outcomes and more variable age of presentation and time to progression than MRT at other sites. Neck MRT may represent a higher-risk subset of MRT, and addition of HDC-ASCR merits consideration.

*Department of Pediatric Hematology-Oncology, Children’s Hospital of San Antonio—Baylor College of Medicine, San Antonio, TX

Departments of Pediatric Hematology, Oncology & Bone Marrow Transplant

Pathology

§Human Oncology

Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI

Department of Pathology and Immunology, Washington University Medical School, St Louis Children’s Hospital, St Louis, MO

Supported by NIH/NHLBI T32 HL07899 and NIH NOT-OD-11-086 (A.D.W.). NIH/NCI K08 CA174750 (C.M.C.).

The authors declare no conflict of interest.

Reprints: Adam D. Wolfe, MD, PhD, Pediatric Hematology-Oncology, Children’s Hospital of San Antonio—Baylor College of Medicine, 333 N. Santa Rosa Street, Suite F3725, San Antonio, TX 78207 (e-mail: adam.wolfe@bcm.edu).

Received October 25, 2016

Accepted March 3, 2017

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.